郭翔 博士

百济神州副总裁，统计和数据科学部全球负责人

郭翔博士毕业于美国北卡州立大学（NCSU）统计系，目前是百济神州副总裁，统计和数据科学部全球负责人。加入百济之前，郭翔博士于2013-2017年担任默沙东实验室生物统计亚太负责人，高级总监，领导默沙东中国位于北京和上海的生物统计团队。郭翔博士在糖尿病，抗感染，肿瘤等治疗领域有丰富的临床试验经验。在赛诺菲工作期间，郭翔博士负责了来得时产品儿童人群适应症的全球申报并获得批准，支持了Rimonabant在欧盟的申请以及Lixisenatide在FDA的申报并获得批准。在默沙东期间，郭翔博士负责了默沙东中国Gardasil 疫苗以及布瑞亭的申请工作并获得上市批准，支持了Keytruda和Zeptier在FDA以及PMDA的申请并获得上市批准。

Isabelle de Zegher

Vice President Integrated Solutions, at PAREXEL Informatics

50 characters or less Isabelle de Zegher is Vice President, Integrated Solutions at PAREXEL Informatics where she is responsible for engineering strategy around Digital Innovation, Big Data, BI and Advanced Analytics. She has 25 years’ experience in Life Sciences, including extensive work on cross-industry forum on integration. Isabelle holds a MD (Belgium) and an MSc in Medical Information Sciences (Stanford University). 300 characters or less Isabelle de Zegher is Vice President Integrated Solutions, at PAREXEL Informatics since 2011 where she is responsible for strategic initiatives related to Digital Innovation, Sensor platform, Artificial Intelligence and Data Sciences; she joined PAREXEL as Senior Director Technology Integration & Data Standards in 2009. She used to be the Novartis Pharma Development Chief Data Officer, after being Global Head Account Management Clinical Development & Medical Affairs for 2 years. Isabelle joined Novartis in 2005 coming from UCB Pharma where she used to be Head of Global Electronic Document Management. Before that, she worked for 8 years at Cap Gemini as a business consultant and subsequently as Director of Life Sciences Consulting, covering Hospital Sector, Public Health, Drug Regulatory Authorities and Pharmaceutical industry. She started her career as a senior researcher in a Belgium company where she managed for 5 years European Research consortia funded by the European Commission as part of the Advanced Informatics in Medicine initiative. Isabelle holds a MD and MSc in Computer Sciences from the University of Louvain, Belgium, and a MSc in Medical Information Sciences from Stanford University, USA. Throughout her career she participated as an expert to several standardization working groups at CEN, ICH and EFPIA level. She used to chair the EFPIA EHR task force and served on the CDISC Board of Directors for 3 years; she co-chaired with FDA the PhUSE - FDA CSS working group on Emerging technology and is/has been co-chairing the Big Data/ Digital Disruptors Theme for DIA Europe.

Alex Zhavoronkov

CEO of Insilico Medicine

Dr. Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He was the first to develop the deep-learned multi-modal predictors of age for drug and biomarker development. He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he published over 120 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy†(Palgrave Macmillan, 2013). He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Raymond A. Huml

IQVIA药物策略开发副总裁 生物类似药卓越中心全球生物类似药策略计划负责人

Raymond A. Huml, MS, DVM, RAC is Vice President of Strategic Drug Development and Head of Global Biosimilars Strategic Planning for IQVIA’s Biosimilars Center of Excellence. Dr. Huml has almost 30 years of experience in the clinical and biopharmaceutical industries. Dr. Huml previously held the position of Head of Global Due Diligence for Quintiles Corporate Development and identified risks associated with Quintiles global, product-based investments, which resulted in over $2.9b in capital committed to partnerships of all sizes. Previously, Dr. Huml worked in the Center for Integrated Drug Development (now Strategic Advisory Services), Biostatistics, Medical Writing, and Regulatory Affairs Departments in Quintiles (legacy) Clinical Development Services group. Dr. Huml has authored or co-authored over 70 articles, 11 book chapters and three books on topics such as due diligence, competitive intelligence, biosimilars and muscular dystrophy. In 2010, he published the first individually authored book for RAPS titled, “Introduction to the Due Diligence Process.” In 2015, Dr. Huml edited and wrote or co-wrote eight chapters for the Springer book titled, “Muscular Dystrophy: A Concise Guide”, which covers all types of MD. According to the 2017 and 2018 Springer Book Performance Reports, it was one of the “top 25% most downloaded eBooks in the relevant SpringerLink eBook Collection in 2016 (and 2017, respectively).” In 2003, he was awarded North Carolina Veterinary Medical Association's Young Veterinarian of the Year Award. In 2004, he was awarded Regulatory Affairs Professional’s Society (RAPS) New Professional Award. He has also received numerous Quintiles awards including the Distinguished Performance Award, Clinical Development Services President's Award and the Chairman's Award. Dr. Huml is a Returned Peace Corps Volunteer having served in Ghana, West Africa and currently sits on North Carolina State University’s Board of Visitors. He holds an MS in Biology from East Stroudsburg University and his DVM from North Carolina State University’s College of Veterinary Medicine and has earned the RAC (US) Certification.

黄超兰

北京大学医学部精准医疗多组学研究中心，主任

黄超兰教授2003年在香港大学取得博士，专业攻读质谱机理，研究多肽的质谱气相热动学及其裂解途径。2005-2007年，为美国斯克里普斯研究所(The Scripps Research Institute ) John R Yates教授实验室访问学者、博士后研究员，开始从事基于质谱的蛋白质组学前沿新技术和方法的研究开发工作。2007年，留任斯克里普斯研究所。2013年1月受中科院人才招聘回国，参与中科院国家蛋白质科学中心的建设。2014年获选为“中科院引进杰出技术人才”。2017年被引进北大医学部，组建北京大学医学部精准医疗多组学研究中心，担任中心主任。黄教授从事质谱技术及基于质谱的蛋白质组学在基础研究和临床研究的方法学开发。发表研究论文65篇（其中归国后2015-2017年发表25篇），包括 Science, Nature Method, Nature Communication，PLoS Biology, PNAS and Molecular Cell，EMBOJ等，H-指数为28。

Simranjit Singh

Guardant Health公司首席执行官

Simranjit Singh is the CEO of Guardant Health AMEA (GH AMEA), Inc., a joint venture between Guardant Health, Inc. & Softbank. He has more than 15 years of senior management experience in Asia Pacific working with biopharma, diagnostics and medical device companies. He leads GH AMEA which is a global leader in precision oncology. GH AMEA’s comprehensive genomic profiling (liquid biopsy) tests are available in 31 different markets across Asia, Middle East & Africa and it has 2 regional offices in Singapore & Tokyo. Prior to Guardant Health, Simranjit was the Vice President of the Medical Devices and Diagnostics Division at IQVIA where he delivered exponential revenue growth by driving business transformation & growing the clinical research, consulting & regulatory business to advance market share in Asia Pacific.

李星

北京深度智耀科技有限公司首席执行官创始人

陈至扬

Medidata Solutions 专业服务部副总裁

Zhiyang got his Ph. D of pharmacology. He has been working in this industry for over 18 years, and is very specialized in clinical data management, biostatistics, eClinical software development, implementation and service delivery etc. He is currently responsible for professional services, enablement training, production localization, technical support in great China, Korea, south east Asia, Australia, New Zealand and India etc. Before he joined Medidata, he was working for some top CROs, government clinical research institutes and software development companies.